Skip to content
Search

Latest Stories

Discontinue cladribine if significant hepatic injury is confirmed, MHRA advises

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised patients to seek urgent medical attention if they develop any clinical features of liver dysfunction.

The agency urged to discontinue or interrupt cladribine if significant hepatic injury is confirmed. It said, "Liver monitoring requirements for cladribine in the treatment of multiple sclerosis have been introduced following uncommon cases of serious liver injury."


Cladribine (Mavenclad) is a nucleoside analogue that causes lymphocyte depletion. It is authorised in the UK for the treatment of adults with highly active relapsing multiple sclerosis as defined by clinical or imaging features.

The recommended cumulative dose of cladribine for multiple sclerosis is 3.5 mg/kg bodyweight over 2 years, divided into 2 treatment courses of 1.75 mg/kg per year. Each treatment course is given over 2 separate weeks: 1 week at the start of the first month and the next week at the start of the following month. Single daily doses are given on 4 or 5 days of each week.

Advise for healthcare professionals:

  • a small number of cases of clinically significant liver injury have been reported during cladribine treatment for multiple sclerosis
  • most events occurred within 8 weeks of the start of the first treatment course of cladribine
  • before starting cladribine check if there is a history of liver disorders, including hepatic injury related to other medicines
  • monitor liver function tests (including total bilirubin) before each treatment course in years 1 and 2; and, if clinically necessary, during treatment
  • urgently check liver function tests (including bilirubin) in patients with symptoms or signs of liver injury
  • discontinue or interrupt cladribine treatment in patients with hepatic dysfunction or unexplained increases in liver enzymes
  • report any suspected adverse drug reactions associated with cladribine on a Yellow Card

Advise for healthcare professionals to give to patients and carers:

  • cladribine treatment for multiple sclerosis has been associated with a risk of serious liver injury – these serious events are uncommon and have most commonly happened in the 8 weeks after starting the first treatment
  • blood tests to check your liver function are needed before the start of each treatment course; you may also need tests during each treatment if your doctor thinks they are needed
  • talk to your doctor straight away if you develop any signs of liver problems such as pain in the upper right area of your stomach, yellowing of your skin or the white part of your eyes, loss of appetite, feeling or being sick, dark urine, or widespread itching
  • read carefully the Patient Guide from your doctor and the Patient Information Leaflet that accompanies your medicine; keep them handy in case you need to read them again.

More For You

Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less
Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less